Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Receivables - Other (2019 - 2025)

Historic Receivables - Other for Legend Biotech (LEGN) over the last 6 years, with Q4 2024 value amounting to $780000.0.

  • Legend Biotech's Receivables - Other fell 126.58% to $780000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $780000.0, marking a year-over-year decrease of 126.58%. This contributed to the annual value of $780000.0 for FY2024, which is 126.58% down from last year.
  • According to the latest figures from Q4 2024, Legend Biotech's Receivables - Other is $780000.0, which was down 126.58% from $790000.0 recorded in Q4 2023.
  • Legend Biotech's 5-year Receivables - Other high stood at $50.0 million for Q4 2021, and its period low was $619000.0 during Q4 2020.
  • For the 5-year period, Legend Biotech's Receivables - Other averaged around $9.0 million, with its median value being $785000.0 (2023).
  • Its Receivables - Other has fluctuated over the past 5 years, first skyrocketed by 797754.44% in 2021, then tumbled by 9810.4% in 2022.
  • Legend Biotech's Receivables - Other (Quarter) stood at $619000.0 in 2020, then soared by 7977.54% to $50.0 million in 2021, then tumbled by 98.1% to $948000.0 in 2022, then fell by 16.67% to $790000.0 in 2023, then decreased by 1.27% to $780000.0 in 2024.
  • Its Receivables - Other stands at $780000.0 for Q4 2024, versus $790000.0 for Q4 2023 and $948000.0 for Q4 2022.